CTLA4 and melanoma: In mouse models of melanoma brain metastasis, the combination of axitinib with anti-CTLA-4 antibodies increases the number of effector T-cells and antigen presentation by dendritic cells, which promotes a reduction on tumor growth and an increase in OS [161].